OB Pharmaceuticals

Formed in 2012 and fully operational in 2014, OB Pharmaceuticals conducts the research and development of new molecules that show promise for the treatment of epilepsy and other seizure related disorders. Epilepsy is a chronic neurological disorder characterized by recurrent and often debilitating seizures. A seizure is an abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and/or involuntary muscle movements. Our Drug Pipeline: OB Pharmaceuticals has developed a new class of therapeutics that act at a unique target in the brain to prevent electrical activity that leads to seizures. Our medications not only stop seizures from occurring in preclinical models of epileptic brains but show promise in preventing seizure development. This activity combined with low or no side effects makes these molecules some of the most promising new preclinical medications currently under development. Executive Summary: OB Pharma is developing novel classes of antiepileptic drugs of higher potency, greater efficacy and less undesirable side effects than the current standard of care. More 120 unique small molecules across two structurally distinct chemical families have been synthesized and screened. These novel compounds establish new intellectual property opportunities for pharmaceutical composition and therapeutic method. Our lead candidates have been screened in both classic and novel proprietary preclinical models of epilepsy and seizures resulting from brain injury, both in vitro and in vivo.